XML 51 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVERSE MERGER (Narrative) (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 29, 2017
Aug. 31, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2017
Business Combination Segment Allocation [Line Items]          
Number of shares converted (in shares)   1,735,419      
Shares converted, value $ 3,000,000     $ 433,000  
New shares issued (in shares)   22,518      
Common stock, shares outstanding (in shares)       449,175 10,196,620
Preferred stock, dividend rate (percentage)     8.00%    
Convertible Debt [Member]          
Business Combination Segment Allocation [Line Items]          
Debt instrument, face amount $ 800,000        
Private Placement          
Business Combination Segment Allocation [Line Items]          
New shares issued (in shares) 107,056        
Consideration received $ 400,000        
Common Stock [Member]          
Business Combination Segment Allocation [Line Items]          
Number of shares converted (in shares) 5,352,847        
Number of shares converted from debt instrument (in shares) 1,414,700        
Preferred Stock [Member]          
Business Combination Segment Allocation [Line Items]          
Number of shares converted (in shares) 7,155        
Number of shares converted from debt instrument (in shares) 802,920        
Share price (in dollars per share) $ 12.20        
Preferred Stock [Member] | Private Placement          
Business Combination Segment Allocation [Line Items]          
New shares issued (in shares) 107,056        
Transgenomics [Member]          
Business Combination Segment Allocation [Line Items]          
Merger transaction, effective date Jun. 29, 2017        
Conversion of debt into stock $ 3,000,000        
Stock price used for estimating purchase consideration (in dollars per share) $ 6.80        
Common stock, shares outstanding (in shares) 895,334        
Preferred stock, dividend rate (percentage) 8.00%        
Transgenomics [Member] | Common Stock [Member]          
Business Combination Segment Allocation [Line Items]          
Number of shares converted from debt instrument (in shares) 352,630        
Conversion of debt into stock $ 3,000,000        
Transgenomics [Member] | Preferred Stock [Member]          
Business Combination Segment Allocation [Line Items]          
Number of shares converted (in shares) 7,155        
Number of shares converted from debt instrument (in shares) 802,925        
Conversion of debt into stock $ 3,000,000